Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureAmna Abdel‐Gadir, Mark A. Westwood
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Disorders of iron metabolism
10.1056/nejm199912233412607 · 1999
A systems biology approach to iron metabolism
10.1007/978-1-4939-2095-2_10 · 2014
Liver iron concentrations and urinary hepcidin in beta-thalassemia
10.3324/haematol.10842 · 2007
Heart disease in thalassemia intermedia
10.3109/03630260903351676 · 2009
Iron overload in non-transfusion-dependent thalassemia: a clinical perspective
10.1016/s0268-960x(12)70006-1 · 2012
Sickle-cell disease and the heart: review of the current literature
10.1111/j.1365-2141.2012.09143.x · 2012
Italian society of hematology practice guidelines for the management of iron overload in thalassemia major and related disorders
10.3324/haematol.12413 · 2008
Cardiac iron overload evaluation in thalassaemic patients using T2∗ magnetic resonance imaging following chelation therapy: a multicentre cross-sectional study
10.1016/j.htct.2021.01.014 · 2023
Low prevalence of cardiac siderosis in heavily iron loaded Egyptian thalassemia major patients
10.1007/s00277-013-1876-0 · 2014
Cardiac magnetic resonance imaging R2∗ assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia
10.3324/haematol.10455 · 2007
How I treat thalassemia
10.1182/blood-2010-08-300335 · 2011
Multislice multiecho T2∗ cardiac magnetic resonance for the detection of heterogeneous myocardial iron distribution in thalassaemia patients
10.1002/nbm.1382 · 2009
Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2∗ magnetic resonance imaging
2017
Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias
10.1111/j.1445-5994.2011.02527.x · 2011
Burden of cardiac siderosis in a thalassemia-major endemic population: a preliminary report from Pakistan
10.1097/mph.0000000000000574 · 2016
Unresolved referenced work
Kept as external metadata until matched
Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?
10.1053/euhj.2000.2011 · 2000
Unresolved referenced work
2009
Myocardial Iron in Thalassemia (MINT) Investigators. International survey of T2∗ cardiovascular magnetic resonance in β-thalassemia major
10.3324/haematol.2013.083634 · 2013
Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1
10.1038/nm1542 · 2007
Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy
10.1007/s00109-005-0029-x · 2006
T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice
10.1111/j.1600-0609.2010.01549.x · 2011
Amlodipine rescues advanced iron overload cardiomyopathy in hemojuvelin knockout murine model: Clinical implications
10.3389/fcvm.2023.1129349 · 2023
Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial
10.1016/j.amjmed.2013.05.002 · 2013
A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major
10.2147/dddt.s211630 · 2019
Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: a randomized double-blind placebo-controlled trial
10.1002/pbc.29564 · 2022
Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment
10.1016/j.cardfail.2010.05.009 · 2010
Pathogenesis and management of iron toxicity in thalassemia
10.1111/j.1749-6632.2010.05544.x · 2010
Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells
10.1182/blood.v83.9.2692.bloodjournal8392692 · 1994
Exploring the “iron shuttle” hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture
10.1067/mlc.2001.116487 · 2001
Physiology and pathophysiology of iron cardiomyopathy in thalassemia
10.1196/annals.1345.047 · 2005
Iron(II) is a modulator of ryanodine-sensitive calcium channels of cardiac muscle sarcoplasmic reticulum
10.1006/taap.1995.1008 · 1995
Molecular bases of cellular iron toxicity
10.1016/s0891-5849(02)00772-4 · 2002
Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis
10.1161/01.cir.30.5.698 · 1964
Cardiac involvement in Cooley’s anemia
10.1111/j.1749-6632.1965.tb54070.x · 1964
Heart failure in beta thalassemia: a 5-year follow-up study
10.1016/s0002-9343(01)00879-8 · 2001
Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2∗ cardiovascular magnetic resonance
10.1111/j.1365-2141.2004.05202.x · 2004
Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia
10.1182/blood.v95.4.1229.004k32_1229_1236 · 2000
Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation
10.1034/j.1600-0609.2003.00075.x · 2003
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction
10.1186/1532-429x-10-12 · 2008
Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American heart association
10.1161/cir.0b013e31829b2be6 · doi-reference
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload
10.1182/blood-2014-07-586677 · doi-reference
Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients
10.1111/ejh.12507 · doi-reference
Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major
10.1186/1532-429x-14-8 · doi-reference
Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients
10.1046/j.1365-2141.2003.04240.x · doi-reference
Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications
10.1016/j.bcmd.2011.03.007 · doi-reference
Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years
10.1097/mph.0b013e3181e015b0 · doi-reference
Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major
10.1111/j.1365-2141.2009.07970.x · doi-reference
Combined therapy with deferiprone and desferrioxamine
10.1046/j.1365-2141.1998.01002.x · doi-reference
Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone
10.1016/j.trsl.2010.05.002 · doi-reference
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia
10.1182/blood-2009-04-217455 · doi-reference
Deferasirox for up to 3 years leads to continued improvement of myocardial T2∗ in patients with beta-thalassemia major
10.3324/haematol.2011.049957 · doi-reference
Continued improvement in myocardial T2∗ over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload
10.3324/haematol.2010.031468 · doi-reference
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance
10.1161/circulationaha.106.648790 · doi-reference
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major
10.1182/blood-2005-07-2933 · doi-reference
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging
10.3324/haematol.2009.019042 · doi-reference
Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2
10.1111/j.1600-0609.2005.00587.x · doi-reference
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia
10.1016/s0140-6736(02)09740-4 · doi-reference
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis
10.1182/blood-2005-07-2948 · doi-reference
Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications
10.1007/s00277-020-04196-y · doi-reference
Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone
10.3324/haematol.2009.009118 · doi-reference
Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian society for thalassemia and hemoglobinopathies
10.1016/j.bcmd.2009.01.002 · doi-reference
Survival and desferrioxamine in thalassaemia major
10.1136/bmj.284.6322.1081 · doi-reference
Iron-chelating therapy for transfusional iron overload
10.1056/nejmct1004810 · doi-reference
Optimizing iron chelation strategies in beta-thalassaemia major
10.1016/s0268-960x(09)70003-7 · doi-reference
Deferasirox: pharmacokinetics and clinical experience
10.1517/17425255.2012.640674 · doi-reference
Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload
10.1111/j.1365-2141.1995.tb03318.x · doi-reference
Iron chelators in treatment of iron overload
10.1155/2022/4911205 · doi-reference
Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients
10.1016/s0090-9556(25)07467-7 · doi-reference
Emerging understanding of the advantage of small molecules such as hydroxypyridinones in the treatment of iron overload
10.2174/0929867033457629 · doi-reference
Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major
10.1182/blood-2003-08-2841 · doi-reference
Infection due to Yersinia enterocolitica in a series of patients with beta-thalassemia: incidence and predisposing factors
10.1086/515025 · doi-reference
Severe infections in thalassaemic patients: prevalence and predisposing factors
10.1111/j.1365-2141.2006.06082.x · doi-reference
Typical manifestation of acute congestive heart failure in patients with Thalassaemia major causing diagnostic delay in the emergency room
10.1016/s1388-9842(03)00102-8 · doi-reference
Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone
10.1186/1532-429x-15-38 · doi-reference
Improved survival of thalassaemia major in the UK and relation to T2∗ cardiovascular magnetic resonance
10.1186/1532-429x-10-42 · doi-reference
Cardiac T2∗ magnetic resonance for prediction of cardiac complications in thalassemia major
10.1161/circulationaha.109.874487 · doi-reference
Determination of iron in cardiac and liver tissues by plasma emission spectroscopy
10.1177/000456328702400510 · doi-reference
In vivo calibration of the T2∗ cardiovascular magnetic resonance method at 1.5 T for estimation of cardiac iron in a minipig model of transfusional iron overload
10.1186/s12968-021-00715-6 · doi-reference
Relation of myocardial T2∗ to right ventricular function in thalassaemia major
10.1093/eurheartj/ehq106 · doi-reference